US equities |
NVDA $221.30 ▼-3.16% MU $914.13 ▼-4.10% AAPL $342.96 ▲+0.50% AMD $570.82 ▼-5.73% META $737.54 ▼-3.27% MSFT $533.69 ▼-1.80% TSLA $367.16 ▼-2.15% SPCX $152.16 ▼-2.80%
FinancialContent

Latest News about BMRN

Recent news which mentions BMRN

< Previous 1 2 3 4 5 6 7 8 Next >
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Tickers ADAP APOP BMRN FWP
Tags APOP ADAP NRXP
From Benzinga
FDA Slaps Clinical Hold on BioMarin's Gene Therapy For Genetic Metabolism Disorder
Tickers BMRN
Tags General Health Care Phase 1 Trial
From Benzinga
Drug For Short-Limbed Dwarfism From Biomarin Wins European Approval
Tickers BMRN
Tags Health Care General achondroplasia
From Benzinga
Get Ready for a Potential Double in This Biopharmaceutical Stock in the Next 6 to 12 Months
Tickers ASND BMRN
Tags ASND BMRN Market News
From Motley Fool
BioMarin Bounces Back With Solid Q2 Earnings, Nudges Up 2021 Guidance
Tickers BMRN
Tags General Briefs News
From Benzinga
BioMarin Pharmaceutical inc (BMRN) Q2 2021 Earnings Call Transcript
Tickers BMRN
Tags BMRN Market News
From Motley Fool
Biomarin Pharmaceutical: Q2 Earnings Insights
Tickers BMRN
Tags Earnings Benzinga BZI/Recaps
From Benzinga
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
Tickers ABCL ABOS ACET ACHL
Tags DMAC MIRM MOR
From Benzinga
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
Tickers ABBV ACIU AGIO AGRX
Tags UBX BIO MYOV
From Benzinga
BioMarin Shares 5-Year Data From Open-Label Trial Of Hemophilia Gene Therapy
Tickers BMRN
Tags Health Care General Phase 2 Trial
From Benzinga
BioMarin Expects EMA's CHMP Opinion In 1H 2022 For Its Hemophilia A Gene Therapy, FDA Resubmission In 2Q'22
Tickers BMRN
Tags Briefs Benzinga News
From Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >